UNLABELLED: Programmed death-1 (PD-1)/B7-H1 costimulation acts as a negative regulator of host alloimmune responses. Although CD4 T cells mediate innate immunity-dominated ischemia and reperfusion injury (IRI) in the liver, the underlying mechanisms remain to be elucidated. This study focused on the role of PD-1/B7-H1 negative signaling in liver IRI. We used an established mouse model of partial liver warm ischemia (90 minutes) followed by reperfusion (6 hours). Although disruption of PD-1 signaling after anti-B7-H1 monoclonal antibody treatment augmented hepatocellular damage, its stimulation following B7-H1 immunoglobulin (B7-H1Ig) fusion protected livers from IRI, as evidenced by low serum alanine aminotransferase levels and well-preserved liver architecture. The therapeutic potential of B7-H1 engagement was evident by diminished intrahepatic T lymphocyte, neutrophil, and macrophage infiltration/activation; reduced cell necrosis/apoptosis but enhanced anti-necrotic/apoptotic Bcl-2/Bcl-xl; and decreased proinflammatory chemokine/cytokine gene expression in parallel with selectively increased interleukin (IL)-10. Neutralization of IL-10 re-created liver IRI and rendered B7-H1Ig-treated hosts susceptible to IRI. These findings were confirmed in T cell-macrophage in vitro coculture in which B7-H1Ig diminished tumor necrosis factor-α/IL-6 levels in an IL-10-dependent manner. Our novel findings document the essential role of the PD-1/B7-H1 pathway in liver IRI. CONCLUSION: This study is the first to demonstrate that stimulating PD-1 signals ameliorated liver IRI by inhibiting T cell activation and Kupffer cell/macrophage function. Harnessing mechanisms of negative costimulation by PD-1 upon T cell-Kupffer cell cross-talk may be instrumental in the maintenance of hepatic homeostasis by minimizing organ damage and promoting IL-10-dependent cytoprotection.
UNLABELLED: Programmed death-1 (PD-1)/B7-H1 costimulation acts as a negative regulator of host alloimmune responses. Although CD4 T cells mediate innate immunity-dominated ischemia and reperfusion injury (IRI) in the liver, the underlying mechanisms remain to be elucidated. This study focused on the role of PD-1/B7-H1 negative signaling in liver IRI. We used an established mouse model of partial liver warm ischemia (90 minutes) followed by reperfusion (6 hours). Although disruption of PD-1 signaling after anti-B7-H1 monoclonal antibody treatment augmented hepatocellular damage, its stimulation following B7-H1 immunoglobulin (B7-H1Ig) fusion protected livers from IRI, as evidenced by low serum alanine aminotransferase levels and well-preserved liver architecture. The therapeutic potential of B7-H1 engagement was evident by diminished intrahepatic T lymphocyte, neutrophil, and macrophage infiltration/activation; reduced cell necrosis/apoptosis but enhanced anti-necrotic/apoptotic Bcl-2/Bcl-xl; and decreased proinflammatory chemokine/cytokine gene expression in parallel with selectively increased interleukin (IL)-10. Neutralization of IL-10 re-created liver IRI and rendered B7-H1Ig-treated hosts susceptible to IRI. These findings were confirmed in T cell-macrophage in vitro coculture in which B7-H1Ig diminished tumornecrosis factor-α/IL-6 levels in an IL-10-dependent manner. Our novel findings document the essential role of the PD-1/B7-H1 pathway in liver IRI. CONCLUSION: This study is the first to demonstrate that stimulating PD-1 signals ameliorated liver IRI by inhibiting T cell activation and Kupffer cell/macrophage function. Harnessing mechanisms of negative costimulation by PD-1 upon T cell-Kupffer cell cross-talk may be instrumental in the maintenance of hepatic homeostasis by minimizing organ damage and promoting IL-10-dependent cytoprotection.
Authors: Elias A Said; Franck P Dupuy; Lydie Trautmann; Yuwei Zhang; Yu Shi; Mohamed El-Far; Brenna J Hill; Alessandra Noto; Petronela Ancuta; Yoav Peretz; Simone G Fonseca; Julien Van Grevenynghe; Mohamed R Boulassel; Julie Bruneau; Naglaa H Shoukry; Jean-Pierre Routy; Daniel C Douek; Elias K Haddad; Rafick-Pierre Sekaly Journal: Nat Med Date: 2010-03-07 Impact factor: 53.440
Authors: M Morita; M Fujino; G Jiang; Y Kitazawa; L Xie; M Azuma; H Yagita; S Nagao; A Sugioka; Y Kurosawa; S Takahara; J Fung; S Qian; L Lu; X-K Li Journal: Am J Transplant Date: 2009-11-04 Impact factor: 8.086
Authors: Zubin M Bamboat; Lee M Ocuin; Vinod P Balachandran; Hebroon Obaid; George Plitas; Ronald P DeMatteo Journal: J Clin Invest Date: 2010-01-19 Impact factor: 14.808
Authors: Yoichiro Uchida; Bibo Ke; Maria Cecilia S Freitas; Haofeng Ji; Danyun Zhao; Elizabeth R Benjamin; Nader Najafian; Hideo Yagita; Hisaya Akiba; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2010-04 Impact factor: 17.425
Authors: Haofeng Ji; Yu Zhang; Xiu-da Shen; Feng Gao; Cynthia Y Huang; Catalina Abad; Ronald W Busuttil; James A Waschek; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2013-01-18 Impact factor: 17.425
Authors: Jin Xu; Zhengze Xue; Cheng Zhang; Yuan Liu; Ronald W Busuttil; Jiamin Zhang; Jerzy W Kupiec-Weglinski; Haofeng Ji Journal: Transplantation Date: 2019-04 Impact factor: 4.939
Authors: Yuan Liu; Tianfei Lu; Cheng Zhang; Jin Xu; Zhengze Xue; Ronald W Busuttil; Ning Xu; Qiang Xia; Jerzy W Kupiec-Weglinski; Haofeng Ji Journal: J Hepatol Date: 2019-06-13 Impact factor: 25.083
Authors: Katarzyna Jaworska; Joanna Ratajczak; Liping Huang; Kristen Whalen; Mana Yang; Brian K Stevens; Gilbert R Kinsey Journal: J Immunol Date: 2014-11-17 Impact factor: 5.422
Authors: Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Nat Rev Gastroenterol Hepatol Date: 2012-12-11 Impact factor: 46.802
Authors: Rebecca A Sosa; Ali Zarrinpar; Maura Rossetti; Charles R Lassman; Bita V Naini; Nakul Datta; Ping Rao; Nicholas Harre; Ying Zheng; Roberto Spreafico; Alexander Hoffmann; Ronald W Busuttil; David W Gjertson; Yuan Zhai; Jerzy W Kupiec-Weglinski; Elaine F Reed Journal: JCI Insight Date: 2016-12-08